The mammary gland undergoes development and regression over the course of the ovarian cycle under the regulation of ovarian hormones. Macrophages are implicated as local mediators of this tissue remodeling and may also affect immune surveillance and tumor incidence. To investigate cycle-related changes in macrophage phenotype, mammary gland cells from naturally cycling Cfms-Gfp mice recovered at estrus, metestrus, diestrus, and proestrus were analyzed by flow cytometry. Macrophage expression of MHCII was highest in the proestrus phase, with a 1.6-fold increase compared to the metestrus phase. Similarly, macrophage expression of CD204 was 1.9-fold higher at proestrus compared to estrus. Conversely, macrophage expression of NKG2D was increased at metestrus and diestrus by 7-fold and 5-fold, respectively, compared to estrus. To investigate hormonal regulation of macrophage phenotype, an ovariectomy and hormone replacement model was utilized. Ovariectomized mice were stimulated with exogenous estradiol and progesterone to induce early alveolar development, then given progesterone receptor antagonist RU486 to elicit alveolar bud regression. Progesterone and estradiol in combination reduced macrophage expression of MHCII and CD204 by 5-fold and 3-fold, respectively, and increased macrophage expression of NKG2D by 4-fold. Administration of RU486, following estradiol and progesterone, reversed the macrophage phenotype. These results reveal an essential requirement for ovarian hormones in regulating macrophage phenotype in the mammary gland and indicate that progesterone is particularly critical for controlling macrophage antigen presentation and immune surveillance capacity. development, estrogen, macrophage, mammary gland, ovarian cycle, progesterone
INTRODUCTION
The mammary gland is composed of a hormonally responsive epithelium embedded within a fatty stroma. In the adult female, the majority of mammary gland development occurs during pregnancy, lactation, and involution, as the ability to produce milk for the newborn is acquired and subsequently lost at the time of weaning. It is less well appreciated that the nonpregnant adult mammary gland also undergoes cycles of development and regression over the course of every ovarian cycle [1] [2] [3] [4] . Following ovulation, epithelial cells proliferate to achieve alveolar development in preparation for potential pregnancy. If pregnancy does not proceed, the newly formed alveolar buds undergo regression and the tissue is remodeled in readiness for the onset of the next ovarian cycle. Development is primarily under the control of progesterone, and the degree of alveolar development positively correlates with serum progesterone concentration [1] . Estradiol also contributes to alveolar development through induction of DNA synthesis and promotion of progesterone receptor expression by mammary gland epithelial cells [5, 6] .
Macrophages have key roles in development and restructuring of the mammary gland during puberty, pregnancy, lactation, and involution [7] [8] [9] . Mammary gland macrophages orchestrate tissue morphogenesis, breakdown, and remodeling through production of matrix remodeling enzymes, angiogenic factors, and growth factors that regulate cell proliferation and differentiation. In estrous cycling mice, macrophages promote both alveolar development and regression in the mammary gland, and their activity is ovarian cycle stage dependent [10] . During the development phase, macrophages promote epithelial cell proliferation and the development of alveolar buds; during the regression phase, macrophages phagocytose dying epithelial cells and promote tissue remodeling.
The cellular changes that occur in the mammary gland during the ovarian cycle have significance in understanding breast cancer risk. In women, the number of years of menstrual cycling correlates strikingly with breast cancer incidence [11] . This raises the question of whether the estrous cycle-related changes in mammary gland structure are accompanied by fluctuations in immune surveillance capability and the potential contribution of macrophages to mammary gland tumor susceptibility.
The diverse phenotypes of macrophages are reflected in their patterns of expression of specific receptors and cell surface molecules that mediate macrophage functionality. Depending on their functional phenotype, macrophages can either protect against tumor development or be coerced by the tumor microenvironment to promote tumor growth [12, 13] . Of interest in susceptibility to tumorigenesis are macrophage surface receptors NKG2D, CD204 (also known as scavenger receptor A and macrophage scavenger receptor 1), and major histocompatibility complex class II (MHCII). Upon recognizing common molecular patterns H60 and Rae1b, expressed on the surface of DNA-damaged cells [14] , macrophages expressing the cell surface receptor NKG2D become activated to release proinflammatory cytokines, recruiting leukocytes to the site of injury through release of chemokines and bioactive mediators such as nitric oxide (NO) [14] . CD204 is involved in recognition and subsequent phagocytosis of apoptotic cells [15] and promotes tolerance to tumor antigens [16] . A genetic variant of CD204 is associated with increased prostate and endometrial cancer risk [17, 18] . The adaptive immune response is generated through presentation of antigens by macrophages and dendritic cells in the context of cell surface receptor MHCII to naive, tumor-specific CD4þ and CD8þ T cells [19, 20] .
In order to effectively orchestrate their diverse roles in mammary gland development, we hypothesized that macrophage phenotype and function is regulated by ovarian steroid hormones. To analyze the effect of ovarian hormones on regulation of macrophage phenotype, we investigated the effect of estrous cycle stage on expression of NKG2D, CD204, and MHCII. We then utilized an ovariectomy and hormone replacement model to investigate the role of estrogen and progesterone in orchestrating cycle-related changes in expression of these markers. Our study shows that macrophage expression of MHCII, CD204, and NKG2D fluctuates considerably over the course of the ovarian cycle and that these phenotype changes are regulated by ovarian hormones. We conclude that hormone-dependent alterations in the phenotype and function of macrophages are linked with mammary gland tissue remodeling but may also have consequences for local immune surveillance and susceptibility to tumor development.
MATERIALS AND METHODS

Animals
All animal experiments were approved by the University of Adelaide Animal Ethics Committee and conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Mice were maintained in specific pathogen-free conditions with controlled light (12L:12D cycle) and temperature at the Laboratory Animal Services Medical school facility.
Cfms-Gfp mice, on a C57Bl/6 background, carry a transgene encoding green fluorescent protein driven by the macrophage-specific Cfms promoter [21] . Adult female Cfms-GFP mice were used in both naturally cycling and hormone replacement studies as described below. Nontransgenic C57Bl/6 mice used as controls.
Estrous cycle stage was determined in naturally cycling mice by cytological evaluation of vaginal smears performed daily at 0930 h as previously described [22, 23] . The mice (aged 10-13 wk) were tracked for at least 1 wk through at least one normal 4-to 5-day estrous cycle. Mice were euthanized at each of the four stages of the estrous cycle (estrus, metestrus, diestrus, and proestrus), and the fourth abdominal pair of mammary glands were dissected.
The hormone replacement regimen is illustrated in Figure 1 . Twelve-weekold mice were ovariectomized and allowed to recover for 7 days. Mice were administered subcutaneous 17b-estradiol (1 lg in sesame oil) and progesterone (1 mg in sesame oil) daily for 3 days. This hormone injection protocol has previously been shown to promote mammary gland alveolar development [24] . Mammary glands from estradiol and progesterone-treated mice were analyzed on Day 4 of the treatment regime. To induce alveolar regression, similar to that which occurs at the proestrus/estrus stage of the cycle, ovariectomized mice were stimulated as before with 3 days of treatment with exogenous 17b-estradiol and progesterone. On the fourth day, mice were injected subcutaneously with the progesterone receptor antagonist mifepristone (RU486; 200 lg in 100 ll sesame oil). RU486 was used to block progesterone action, effectively inducing progesterone withdrawal. The dose was chosen, as it has been used previously to investigate the effect of progesterone withdrawal in a mouse model of menstruation [25] . Mammary glands from estradiol and progesteronetreated mice followed by RU486 administration were analyzed on Days 5 and 6 of the treatment regime.
Whole Mount Preparations
Mammary glands were prepared as whole mounts on a glass slide and fixed with Carnoy fixative (2-4 h) followed by carmine alum staining overnight (http://mammary.nih.gov/tools/histological/Histology). Images of the glands were taken using a light microscope (Leica MZ16FA stereo microscope; Adelaide Microscopy).
Immunohistochemistry
Mammary glands were prepared as whole-mount glands on a glass slide and fixed with 4% paraformaldehyde in PBS overnight at 48C. Glands were removed from the slide and embedded in paraffin. Images of hematoxylin and eosin (H&E)-stained 5-lm sections were captured using a Hamamatsu Protonics Nanozoomer and blinded analysis was performed. Epithelium was categorized as ductal or alveolar. The classification system was similar to that of Fata et al. [1] ,whereby ductal epithelium was defined as an epithelial cell layer (analogous to Grade 0), and alveolar epithelium was defined as clusters of epithelial structures containing alveolar lumens (analogous to Grade 3); 60-100 epithelial structures were counted for each mouse and classified as ductal or alveolar epithelium.
To localize smooth muscle actin, 5-lm paraffin sections were blocked with 2% bovine serum albumin (Sigma) for 30 min at room temperature before immunostaining with alkaline phosphatase-conjugated, mouse anti-mouse monoclonal antibody (mAb) reactive with alpha smooth muscle actin (1:30 dilution; 1 h at room temperate; Sigma). Slides were washed in PBS before incubating with Fast red TR/Naphthol AS-MX Phosphate (Sigma) for 10 min and counterstaining with hematoxylin solution (Sigma). Images of the stained sections were captured using a Hamamatsu Protonics Nanozoomer.
Proliferating cells were identified by BrdU immunostaining of paraffinembedded mammary gland tissue. Sections were stained for BrdU incorporation into DNA using a BrdU In-Situ Detection Kit (BD Pharmingen), according to the manufacturer's instructions. Apoptotic cells were identified by TUNEL staining of paraffin-embedded mammary glands. Sections were stained with InSitu Cell Death Detection Kit, Fluorescein (Roche Diagnostics), according to the manufacturer's instructions.
Flow Cytometry
Flow cytometry was utilized in order to define and quantify the macrophage phenotype. Fourth abdominal mammary glands from Cfms-GFP mice were dissected, and the lymph node was removed. The glands were finely minced 
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and digested to generate single-cell suspensions in PBS containing 10% heatinactivated fetal calf serum (FCS; Sigma), 40 U/ml collagenase (Roche), 0.002 g/ml dispase II (Roche), and 25 lg/ml Dnase I (Sigma) for 60 min at 378C, before filtering through a 70-lm nylon cell strainer.
Mammary gland single cell suspensions were incubated for 30 min with combinations of biotin-conjugated rat anti-mouse mAbs to CD204/SRA (1:50 dilution; Serotec) and NKG2D (1:50; eBioscience), with PE-conjugated rat anti-mouse mAb to F4/80 (eBioscience) or MHCII (neat supernatant; ATCC no. TIB120). Cell suspensions were then washed using PBS containing 1% FCS followed by 30-min incubation with streptavidin-conjugated allophycocyanin (eBioscience) or phycoerythrin (PE)-Cy5 (BD Pharmingen). Finally, cells were fixed in 1% paraformaldehyde. Isotype-matched control mAbs were used to gate positively stained cells.
Cells were analyzed using FACS Canto and FACS Diva software (BD Biosciences).
Serum Hormone Analysis
Estradiol and progesterone were quantified in mouse serum by radioimmunoassay. Approximately 1 ml of blood was collected by cardiac puncture under deep Avertin anesthesia. The blood was incubated at 48C overnight and then centrifuged at 4000 rpm (1500 3 g) for 4 min to recover serum. Serum samples were stored at À808C until analysis using commercial radioimmunoassay kits DSL-4800 and DSL-3400 for progesterone and estrogen respectively, according to the instructions of the manufacturer (Diagnostic Systems Laboratories). All samples were measured in a single assay. The within-assay coefficients of variation were 10.0% in the estradiol assay and 7.9% in the progesterone assay. The lower limits of detection were 5 pg/ml estradiol and 0.3 ng/ml progesterone.
Statistical Analysis
Data were analyzed by the Student t-test with significance inferred at P , 0.05.
RESULTS
Initially, we confirmed that the expected morphological changes in the mammary gland occur in naturally cycling Cfms-Gfp mice. At estrus, primary epithelial ducts were observed with some secondary branches and very little alveolar budding ( Fig. 2A) . At diestrus stage, a high abundance of alveolar buds were evident (Fig. 2B ). These changes in mammary gland morphology over the ovarian cycle are similar to those previously described in other strains of mice [1, 26] .
Serum estradiol and progesterone were also quantified in cycling Cfms-Gfp mice ( Table 1) . As expected, serum estradiol was highest at the estrus stage of the ovarian cycle and lowest at diestrus. Conversely, serum progesterone was highest at the diestrus stage and lowest at estrus.
The phenotype of macrophages in Cfms-Gfp mice was then analyzed by flow cytometry. The lineage-defining macrophage marker F4/80 reacted with .90% of GFP-positive cells in Cfms-Gfp mice (Fig. 2D) . GFP-positive cells were not observed in cells from nontransgenic mammary glands (Fig.  2C) . Analysis of surface expression of macrophage phenotype markers on GFP-positive cells from naturally cycling Cfms-Gfp mammary glands revealed fluctuations in macrophage phenotype across the ovarian cycle. Both MHCII and CD204 peaked at proestrus, with MHCII expression elevated 1.6-fold at proestrus compared to metestrus (Fig. 2, E-H) , and CD204 increased 1.9-fold from estrus to proestrus. (Fig. 2, I-L) . Conversely, NKG2D was expressed on very few macrophages during both the proestrus and the estrus phase (Fig. 2, M-P) , with a 7-fold and 5-fold increase expression observed at metestrus and diestrus, respectively, compared to estrus.
These observations implicate a significant effect of ovarian steroid hormones in regulating mammary gland macrophage phenotype and suggest a key role for progesterone, particularly in inducing NKG2D expression, since the profound change in this marker coincides with progesterone increase at metestrus and diestrus. In order to further investigate regulation of macrophage phenotype by progesterone, we utilized an ovariectomy and hormone-replacement model. Ovariectomy of mice resulted in a severe reduction in alveolar bud formation such that the vast majority of mammary epithelium was ductal epithelium (Fig. 3, A and B, for whole mount and H&E, respectively). Administration of exogenous estradiol and progesterone together induced early alveolar development, confirming the hormone dependence of this process. Epithelial ducts with alveolar budding were clearly evident in H&E-stained sections (Fig. 3, E and F) and were structurally similar to those seen in diestrus mice (Fig. 3, C and D ; low-and highpower micrographs of whole mount). Active proliferation, observed by BrdU incorporation, was observed in both the ductal and the alveolar epithelium (Fig. 3G) . and the characteristic layer of smooth muscle actin surrounding alveoli is evident (Fig. 3H) .
Intact alveolar buds persisted for several days after exogenous hormone supplementation was withdrawn (Fig.  4A) , with distinct alveolar buds, intact smooth muscle actin (Fig. 4B) , and no evidence of apoptosis (Fig. 4C ) still present on Day 6, 3 days after the final hormone injection. However, administration of the progesterone receptor antagonist RU486 caused extensive and near complete breakdown and remodeling of the newly developed alveoli. Regression of alveolar buds was observed as early as 24 h following RU486 (Fig. 4D) , with maximal regression 48 h post-RU486 (Fig. 4 , E and F; lowand high-power micrographs of whole mount). Structural alteration to the smooth muscle actin layer (Fig. 4G) and appearance of TUNEL-positive ductal and alveolar epithelial cells (Fig. 4, H and I, respectively) occurred 24 h post-RU486 administration, demonstrating the significance of progesterone withdrawal in alveolar regression.
The morphological changes that occur in the mammary gland in response to hormone stimulation were quantified and compared to the changes during the natural cycle. The proportion of epithelial structures identified as alveolar epithelium within the mammary gland of estradiol-and progesterone-treated mice (Fig. 5A ) was similar to that of naturally cycling mice in the diestrus stage of the ovarian cycle (Fig. 5B) . The proportion of alveolar epithelium in the mammary gland of mice treated with hormones followed by RU486 (Fig. 5A ) was similar to that of naturally cycling mice in the estrus stage of the cycle (Fig. 5B) . This confirms that the structural changes elicited in the mammary gland by exogenous hormone treatment are comparable to the physiological changes of the cycle. However, as the duration and kinetics of hormone stimulation are not identical to naturally cycling mice, this hormone-replaced model is not expected to fully mimic the estrous cycle.
We then investigated the effects of hormone manipulation on macrophage phenotype. Administration of estradiol and progesterone resulted in significant changes to the macrophage populations in the mammary gland. Compared with the hormone-deficient ovariectomized control, MHCII and CD204 were suppressed by exogenous hormone administration, with a 5-fold decrease in the proportion of macrophages expressing MHCII (Fig. 6A) and a 3-fold decrease in macrophages expressing CD204 (Fig. 6B) . Conversely, a 4-fold increase in NKG2D was observed (Fig. 6C) . To evaluate the requirement for progesterone in sustaining this phenotype, additional cohorts of mice were given estradiol and progesterone followed by RU486 to inhibit progesterone receptor signaling and induce mammary gland regression. Twenty-four hours following RU486 administration (Day 5 of the treatment regime), the proportion of macrophages expressing MHCII and HORMONAL REGULATION OF MAMMARY GLAND MACROPHAGES CD204 increased 3.5-fold and 3-fold, respectively, compared to estradiol-and progesterone-treated mice. A 2-fold decrease in the proportion of macrophages expressing NKG2D was also observed. This shift in macrophage phenotype was evident within 24 h of RU486 administration, by which time macrophages were comparable to those in unstimulated ovariectomized mice. Similar changes in expression of MHCII and NKG2D were also observed 48 h following RU486 administration (Day 6 treatment regime; Fig. 6 , A and C), while a further 2-fold decline in CD204 was evident at 48 h compared with 24 h post-RU486 (Fig. 6B) .
DISCUSSION
The hormone-induced morphological changes in the mammary gland across the ovarian cycle pose unique Mammary gland cells from Cfms-Gfp mice were stained with antibodies against MHCII (E-H), CD204 (I-L), or NKG2D (M-P). Example of dot plots of antibody and GFP double fluorescence (E, I, and M). Example of histograms of antibody staining within the GFP-positive cell population from mammary glands in negative control (F, J, and N) and positively stained (G, K, and O) Cfms-Gfp mice. Quantification of percent of MHCII (H), CD204 (L), and NKG2D (P)-positive cells within the GFP-positive cell population in mammary gland from Cfms-Gfp mice at the estrus, metestrus, diestrus, and proestrus phase of the ovarian cycle (E, M, D, and P, respectively). Mean þ SEM, n ¼ 8-12 per group; columns assigned a differ significantly from columns assigned b, and columns assigned ab do not differ significantly from a or b; Student t-test, P , 0.05.
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challenges for the immune system. Macrophages function both to promote the proliferation and differentiation of epithelial cells and to phagocytose dying epithelial cells and remodel the tissue back to a basic architecture [10] . Expedient removal of these dying epithelial cells by rapid macrophage-mediated phagocytosis is likely to be necessary to prevent harmful inflammation [27] and the generation of adaptive immune responses to tissue-specific antigens that could scar the mammary gland and impair subsequent lactation.
However, these changes in macrophage phenotype might also have broader implications for tissue homeostasis and tumor susceptibility. Macrophages promote tumorigenesis through production of growth factors and cytokines, facilitating immune tolerance and suppression of adaptive antitumor immunity and can also promote tumor cell motility and metastasis [28] . Furthermore, macrophages are an active component of the stem cell niche, which is crucial in tumor development as well as tissue homeostasis [29] .
Fluctuation in Macrophage Phenotype Across the Ovarian Cycle
Despite the strong correlation between years of menstrual cycling and breast cancer risk in women, the cell-to-cell interactions that control morphological changes in mammary gland epithelium over the course of the menstrual cycle have not been well described. These cellular interactions clearly affect mammary cancer susceptibility, as the development (diestrus) phase of the ovarian cycle appears to be more resistant to mammary gland tumor initiation compared with the regression (proestrus) phase [30] .
The percent of macrophages expressing MHCII and CD204 during the ovarian cycle is highest at proestrus, when apoptosis of newly formed alveolar epithelium occurs. CD204 is a multifunctional receptor involved in the recognition and phagocytosis of lipoproteins, bacteria, and apoptotic cells [15] , so high expression of this receptor during the regression phase of the cycle would be consistent with recovery from this breakdown phase. CD204 also suppresses MHCII-restricted antigen-specific CD4þ T-cell responses [31] . Thus, through phagocytosis and antigen presentation of dying epithelial cells, CD204 and MHCII might act together to suppress T-cell activation and dampen harmful inflammatory or autoimmune responses. However, induction of tolerance to tumor-associated antigens [16] can also result from antigen presentation, and thus increased expression of these receptors would not be inconsistent with the higher susceptibility to tumorigenesis during the regression phase of the ovarian cycle [30] .
NKG2D is most commonly detected on natural killer cells; however, it has also been described on subsets of macrophages and T cells [14, 32, 33] . NKG2D is a cell surface receptor that is able to recognize multiple stress-induced proteins on damaged cells [34] , facilitating secretion of nitric oxide by macrophages and tumor cell cytostasis [35] . Macrophage NKG2D expression is observed in the metestrus and diestrus phase of the cycle but is virtually absent at estrus and proestrus. NKG2D has not previously been investigated in the mammary gland, and its significance in mammary tumor immune surveillance is not clear. However, on the basis of the known function of NKG2D-expressing macrophages in other tissues, it seems reasonable to speculate that its expression might aid in the detection and elimination of DNA-damaged target cells. This prediction is consistent with the development phase of the cycle being relatively resistant to tumorigenesis compared to the regression phase [30] .
These observations show that a rapid and dramatic shift in phenotype accompanies the previously described fluctuations in macrophage abundance through the ovarian cycle [10] . However, it is unclear whether this change in phenotype reflects an influx of new macrophages or dynamic redistribution of receptor expression within persisting resident macrophages. Macrophage abundance in the mammary gland rises at metestrus, is maximal at diestrus, and declines by half at proestrus. Macrophages expressing NKG2D could therefore reasonably be a new macrophage population recruited during the development phase of the cycle before exiting at the onset of regression. Consistent with the possibility of a dynamic population of NKG2D-positive macrophages and a more stable population of macrophages expressing MHCII and CD204, the 
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latter population is increased coincidently with the dramatic fall in total macrophage abundance. However, this possibility clearly requires further investigation, as the alternative notion of a single population of cells with high plasticity, controlled by dynamic patterns of microenvironmental cues, cannot be excluded.
Regulation of Macrophage Phenotype by Ovarian Hormones
To explore hormonal regulation of macrophages in vivo, we utilized an ovariectomy and hormone replacement model in mice. Administration of estradiol and progesterone to ovariectomized mice elicited epithelial cell proliferation and the development of clusters of alveolar epithelial cells morphologically comparable to those observed at the diestrus phase of the ovarian cycle. Our preliminary studies showed that when hormone treatment is withdrawn, the alveolar buds remain intact for at least the next 3 days, presumably due to sufficient residual hormones. However, acute suppression of progesterone signaling by administration of the progesterone receptor antagonist RU486 elicited rapid induction of apoptosis in the newly formed alveolar epithelium and caused remodeling of the mammary gland to a morphological state comparable to that observed at the estrus phase of the natural cycle. These findings suggest that progesterone is essential for generation of the nascent alveolar budding seen at the diestrus phase of the cycle and that the principal driver of mammary gland regression at proestrus in naturally cycling mice is progesterone withdrawal. However, it is important to note that this mouse model does not fully mimic the estrous cycle, with differences in the pattern of hormone exposure and in the kinetics of tissue remodeling between the natural and artificial model. Thus, there may be additional complexity in the cellular and molecular changes of the natural cycle that are not replicated in this hormone-replaced model.
Whether macrophage phenotypes are directly regulated by ovarian hormones through receptor-mediated activation or indirectly regulated by the hormonally responsive mammary gland epithelium is yet to be elucidated. Direct regulation of macrophages has been demonstrated in vitro, where progesterone suppresses expression of toll-like receptor 4, inducible nitric oxide synthase, and activation of nuclear factor-kappaB [36, 37] . However, mammary gland macrophages have close physical associations with epithelial cells, and it seems likely that a regulatory nexus akin to the macrophage-epithelial crosstalk in the female reproductive tract may exist. In the uterus, luminal and glandular epithelial cells produce a wide range of cytokines and chemokines in response to ovarian steroid hormone stimuli [38, 39] , which in turn control the movements and phenotype of local macrophages [40] . Similarly, paracrine regulation of macrophage function is also likely to occur in the mammary gland. The abundance and activation of mammary epithelial cell-derived TGFB1 is dependent on estrous cycle stage [41] and regulates the phenotype of mammary gland macrophages [42] . Although cytokine production by mammary gland epithelial cells has not been extensively examined, an array of cytokines, including interleukin 2 and 4, interferon gamma, and tumor necrosis factor alpha, are differentially produced in the mammary epithelial cell line KIM2, dependent on hormone-induced differentiation status [43] .
In conclusion, this study provides compelling evidence that ovarian steroid hormones estradiol and progesterone profoundly affect the phenotype of macrophages in the mammary gland. This study supports the notion of two distinct patterns of macrophage phenotype, with a shift in their relative balance depending on hormone status. In broad terms, it appears that sufficient estrogen and progesterone are required to support macrophages expressing low MHCII and CD204 and high NKG2D. In contrast, progesterone withdrawal causes a reversal in the relationship between these phenotype markers, most predominantly affecting NKG2D, which is substantially diminished after progesterone withdrawal, either at the time of proestrus in the natural cycle or after RU486 administration. This fluctuation in macrophage phenotype over the course of the ovarian cycle implies that mammary gland macrophages would have differential capability to recognize DNA-damaged cells and phagocytose and present antigens to generate adaptive immune responses. This changing macrophage function across the ovarian cycle is likely to reflect the requirement for macrophages to support tissue development versus tissue degeneration. However, this might also impact on immune responses to the early stages of tumorigenesis and dispose to the increased breast cancer susceptibility observed in women with increased number of years of menstrual cycling. FIG. 5 . Percent of epithelium classified as alveolar in ovariectomized hormone-treated (A) and naturally cycling (B) mice. Mammary gland tissue from estradiol-and progesterone-treated mice was analyzed on Day 4 of the treatment regime, and tissue from estradiol-and progesteronetreated followed by RU486 administration was analyzed on Day 6. Mammary gland tissue was analyzed from naturally cycling mice in the estrus, metestrus, diestrus, and proestrus (E, M, D, and P, respectively) phase of the cycle. Mean þ SEM, n ¼ 8-12 per group; columns assigned a differ significantly from columns assigned b and differ from columns assigned c. Columns assigned ab do not differ significantly from a or b; Student t-test, P , 0.05.
FIG. 6. Quantification of percent of MHCII (A), CD204 (B)
, and NKG2D (C) positively stained cells within the GFP-positive cell population in ovariectomized unstimulated Cfms-Gfp mice, estrogen-and progesteronetreated mice (Day 4 of the treatment regime), and estrogen-and progesterone-treated mice followed by RU486 administration (Days 5 and 6 of the treatment regime). Mean þ SEM, n ¼ 8-12 per group; columns assigned a differ significantly from columns assigned b, and columns assigned ab do not differ significantly from a or b; Student t-test, P , 0.05.
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